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Abstract
Cross-reactive dengue virus (DENV) antibodies directed against the envelope (E) and precursor membrane (prM) proteins
are believed to contribute to the development of severe dengue disease by facilitating antibody-dependent enhancement
of infection. We and others recently demonstrated that anti-prM antibodies render essentially non-infectious immature
DENV infectious in Fcc-receptor-expressing cells. Immature DENV particles are abundantly present in standard (st) virus
preparations due to inefficient processing of prM to M during virus maturation. Structural analysis has revealed that the E
protein is exposed in immature particles and this prompted us to investigate whether antibodies to E render immature
particles infectious. To this end, we analyzed the enhancing properties of 27 anti-E antibodies directed against distinct
structural domains. Of these, 23 bound to immature particles, and 15 enhanced infectivity of immature DENV in a furin-
dependent manner. The significance of these findings was subsequently tested in vivo using the well-established West Nile
virus (WNV) mouse model. Remarkably, mice injected with immature WNV opsonized with anti-E mAbs or immune serum
produced a lethal infection in a dose-dependent manner, whereas in the absence of antibody immature WNV virions caused
no morbidity or mortality. Furthermore, enhancement infection studies with standard (st) DENV preparations opsonized
with anti-E mAbs in the presence or absence of furin inhibitor revealed that prM-containing particles present within st virus
preparations contribute to antibody-dependent enhancement of infection. Taken together, our results support the notion
that antibodies against the structural proteins prM and E both can promote pathogenesis by enhancing infectivity of prM-
containing immature and partially mature flavivirus particles.
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Introduction
Dengue virus (DENV) is the leading cause of mosquito-borne
viral disease in the world. It is estimated that over 50 million
DENV infections occur annually, resulting in 500,000 hospital-
izations and over 20,000 deaths [1]. The four antigenically distinct
serotypes (DENV 1, 2, 3 and 4) are transmitted to humans by bites
of female Aedes aegypti and Aedes albopictus [1,2]. Although most
infections are asymptomatic, DENV infection may result in a wide
spectrum of clinical symptoms, ranging from a febrile illness
(dengue fever [DF]) to a life-threatening hemorrhagic and
capillary leak syndrome (dengue hemorrhagic fever [DHF]/
dengue shock syndrome [DSS]) [1,2].
The immunopathogenesis of dengue is not fully understood.
Infection with one serotype provides lifelong protective immunity
to the homologous infecting serotype and cross-protection in the
first few months against the other serotypes. However, individuals
experiencing a later secondary infection with a distinct DENV
serotype are at greater risk for developing severe disease.
Additionally, in 6 to 9 month-old children of dengue immune
mothers, severe disease is associated with primary infection,
possibly because of waning levels of neutralizing maternal
antibodies [3,4]. This latter observation has been the basis for
the now widely accepted hypothesis of antibody-dependent
enhancement (ADE) of infection as an explanation for the
development of DHF/DSS upon infection [5,6]. Cross-reactive
antibodies at sub-neutralizing concentrations are believed to
promote virus uptake and infection of Fc-y-receptor-bearing cells,
leading to enhanced replication and a more pronounced
inflammatory response early in infection [6,7].
DENV is an enveloped, positive-stranded RNA flavivirus. The
virion contains three structural proteins, capsid (C), envelope (E)
and membrane (M). In the infected cell, M is formed as a
precursor protein called prM. The prM protein acts as a
chaperone for correct folding and stabilization of the E protein
during virus assembly and egress [8,9]. E is the primary envelope
glycoprotein that mediates the infectious cell entry of flaviviruses
[2]. The atomic structure of the E protein ectodomain is organized
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domain and participates in the conformational changes required
for membrane fusion [12], domain II (DII) contains the highly
hydrophobic fusion loop that is inserted into the target cell
membrane during the endosomal membrane fusion process
[13,14,15], and domain III (DIII) has an immunoglobulin-like
structure and is believed to be involved in virus attachment to the
cell surface [10,16,17].
Cells infected with DENV secrete a heterogeneous mixture of
structurally distinct virus particles varying from fully immature,
partially mature to mature [18,19,20,21]. These virus particles can
be distinguished by their difference in size, surface morphology,
and the cleavage status of the prM protein [8,22,23]. Recent
studies found that at least 30–40% of DENV particles released
from infected mosquito cells contained prM molecules [21,24].
The heterogeneity in prM protein expression is caused by
inefficient cleavage of prM to M by the host protease furin during
virus maturation [25] and can influence the neutralizing and
enhancing capacity of antibodies directed against the viral surface
proteins [26,27,28]. Indeed, anti-prM antibodies render essentially
non-infectious immature particles highly infectious [26,28].
Analogous to virus particle maturation during egress, the
internalized antibody-opsonized immature virus particles are
processed by cellular furin present in the endocytic pathway,
thereby allowing virus infection [26,29].
The E protein is a major target in the immune response to
DENV, and structural analysis demonstrated that some E epitopes
are preferentially exposed in immature virions [18]. We recently
observed that a weakly neutralizing West Nile virus (WNV) fusion
loop antibody has the capacity to render immature WNV particles
infectious [30]. The intrinsic ability of E fusion loop antibodies,
which are immunodominant in the human humoral response
against flaviviruses [31,32,33,34], to render immature particles
infectious may therefore pose a threat for the development of a
safe and efficacious vaccine against DENV.
In this study, we analyzed the functional properties of a pool of
27 mouse monoclonal antibodies recognizing distinct structural
domains to gain a detailed insight in the neutralizing versus
enhancing capacity of E antibodies towards immature DENV
particles. We found that the majority of antibodies directed against
both E DI/II and E DIII can render immature DENV particles
infectious in a furin-dependent manner. Furthermore, opsoniza-
tion of immature WNV with anti-E mAbs and diluted immune
serum can cause lethal disease in mice. Thus, in addition to anti-
prM antibodies, the vast majority of anti-E antibodies tested can
facilitate viral infectivity of immature flavivirus particles, and this
may have adverse consequences in vivo.
Results
Antibodies against the E protein bind to immature
dengue virus particles
Initially, we investigated whether anti-E antibodies have the
capacity to bind immature DENV particles. Immature DENV-2
strain 16681 particles were produced with an average prM content
of 94%69% in furin-deficient LoVo cells, as described previously
[21]. The specific infectivity of the LoVo-derived virus preparation
used in this study was 100,000-fold lower compared to that of st
virus preparations produced on C6/36 mosquito cells. This is
consistent with our earlier results [21,26] and confirms that
immature virus is essentially non-infectious.
The anti-DENV-2 mouse mAb panel used was reported
previously and generated after immunization with live DENV-2
strains 16681 and NGC [35]. From this panel, we selected 25 mAbs
including 13 that mapped to DIII, 11 that localized to E DI/DII,
and 1 that bound E but could not be mapped by yeast surface
display of E proteins. The known characteristics of these antibodies
are summarized in table 1 (adapted from [35]). Additionally, we
tested2 commercial mAbs, 3H5(DIII) and4G2(DI/DII).AllmAbs
were tested for binding to immature DENV virions by direct
ELISA. We observed that 85% of the E-specific DENV antibodies
bound to immature particles (Table 1). No consistent difference in
binding was seen among mAbs that recognized DI/DII or the DIII
domain (43% and 52% positivity, respectively).
Anti-E antibodies promote infectivity of immature DENV
Next, we investigated if the mAbs that bind to immature virus
would promote infectivity in murine macrophage-like P388D1 cells,
which express three different Fc gamma receptors (FccRs), FccRIII
[CD16], FccRII [CD32], and FccRI [CD64]) [36,37]. Prior to
infection of P388D1 cells, immature DENV was pre-incubated for
1h ra t3 7 uCinthepresence orabsence ofincreasing concentrations
of anti-prM or anti-E antibodies and added to P388D1 at a
multiplicity of 1000 genome-containing particles (GCP) per cell
(MOG 1000) as determined by quantitative PCR (qPCR) analysis.
At 43 hr post-infection (hpi), the supernatant was harvested, and
infectious virus production was analyzed by plaque assay on
BHK21-15 cells. Consistent with previous studies [26,28], imma-
ture DENV particles became infectious in the presence of anti-prM
with titers comparable to that of st virus preparations in the absence
of antibody (Fig. 1A). Of the 23 E mAbs tested, 15 mAbs (65%)
facilitated infectivity of immature DENV particles (Table 1).
However, different patterns of enhancement were observed. MAbs
4G2 (DI/II), DV2-29 (DI/II), DV2-48 (DI/II), DV2-60 (E), DV2-
76 (DIII), and DV2-96 (DIII) (Fig. 1C, D, G, J, M, and O,
respectively) promoted infectivity of immature DENV over a broad
antibody concentration range and to levels comparable of infection
of st DENV particles in the absence of antibodies. In comparison,
DV2-38 (DIII) (Fig. 1E) enhanced viral infectivity at all
concentrations tested, albeit with lower efficiency. MAbs 3H5
(DIII), DV2-44 (DI/II), DV2-53 (DI/II), DV2-58 (DI/II), DV2-70
(DIII),DV2-73(DIII),DV2-77(DIII)andDV2-104(DIII)(Fig.1B,
F, H, I, K, L, N, and P, respectively) modestly promoted viral
infectivity of immature DENV, and only at higher antibody
concentrations. Thus, anti-E DI/II and anti-E DIII antibodies have
the capacity to rescue the infectivity of immature DENV particles.
Notably, whereas enhancement of infection of immature DENV
particles opsonized with anti-prM antibodies was more readily seen
at lower antibody concentrations (Fig. 1A) and [26,28], enhance-
ment of infection mediated by most anti-E antibodies was
preferentially observed at higher antibody concentrations. Interest-
ingly, six mAbs that mapped to DIII and six mAbs that localize to
DI/DII (Table 1) failed to promote viral infectivity of immature
particles in P388D1 cells at any antibody concentration tested.
These mAbs also failed to promote viral infectivity of immature
particles in human U937 cells (data not shown).
Anti-E mAbs facilitate binding of immature DENV
particles to cells
To investigate if mAbs directed against E, analogous to that
seen with enhancing anti-prM antibodies [26], promote uptake of
immature DENV particles in cells, we performed a cell binding
and internalization assay using qRT-PCR [38]. For this purpose,
we selected a subset of enhancing and neutralizing anti-DENV-2
mAbs directed against distinct domains of the E protein. DENV-
immune complexes were added to P388D1 cells at a MOG of
1000 and incubated for 1 hr at 37uC. All tested anti-E antibodies
facilitated cell binding and internalization of immature particles to
Infectivity of Anti-E Bound Immature Flaviviruses
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immature particles in the absence of antibody (Fig. 2). Antibody-
opsonized immature particles appeared to bind to cells as
efficiently as or even slightly better (mAbs DV2-60, DV2-48 and
DV2-53, P,0.01) than st DENV in the absence of antibody. The
neutralizing mAbs DV2-30, DV2-40 and DV2-67 bound to a
somewhat lower extent to cells than st DENV particles, albeit to
comparable levels as the enhancing anti-E mAbs 4G2, DV2-96
and DV2-104. This suggests that neutralization of infection by
these mAbs likely occurs in part, at a post-attachment stage after
binding of the virus-immune complexes to cells.
Enhancement of immature DENV infectivity by anti-E
mAbs is furin-dependent
The enzymatic activity of furin is crucial for rendering
immature DENV particles infectious after opsonization with
anti-prM mAbs [26]. As such, we investigated whether furin
activity also was required for the infectivity of immature particles
opsonized with anti-E mAbs by treating P388D1 cells with furin
inhibitor (FI), decanoyl-L-arginyl-L-valyl-L-lysyl-L-arginyl-chloro-
methylketone (decRRVKR-CMK) prior to and during infection.
The half-life of FI in cells is approximately 4–8 hrs [39]. This was
confirmed in a control experiment in which P388D1 cells were
infected with st DENV particles with and without FI treatment.
Notably, addition of FI to P388D1 cells did not reduce infectivity,
indicating that for st DENV FI is no longer active when progeny
virions are released from the infected cell (Fig. 3). Instead,
repeated addition of FI to the producer cell at the time of virion
assembly markedly reduced the formation of infectious particles
implying that under these conditions only non-infectious immature
particles are being released (data not shown and [26]). The latter
control confirms that FI actively interferes with furin activity.
Notably, inhibition of furin activity in target cells abolished
infectivity of antibody-opsonized immature virions, demonstrating
that furin activity during the entry stage is crucial for rendering
DENV-immune complexes infectious (Fig. 3).
Anti-E-mediated enhancement of infectivity of prM-
containing particles from standard DENV preparations
Multiple studies have shown that anti-E mAbs facilitate ADE of
st DENV preparations [40,41,42]. Here, we show that anti-E
mAbs promote infectivity of immature virions. As the accessibility
Table 1. Profile of the antibodies tested.
MAb Binding domain
a Isotype % Neutralization
b Cross-reactivity Elisa prM DENV
c prM-DENV infectivity
DENV2-3H5 E DIII IgG1 n.d.
d none ++
DENV2-4G2 E DI, II IgG2a n.d.
d DENV1,3,4, WNV ++
DENV2-29 E DI, II IgG3 100 DENV1,3,4, WNV ++
DENV2-30 E DI, II IgG2c 100 DENV1,3,4 + 2
DENV2-32 E DI, II IgG2c 100 none + 2
DENV2-33 E DI, II IgG2c 0 DENV3 22
DENV2-38 E DIII IgG3 56 none ++
DENV2-40 E DI, II IgG2b 100 none + 2
DENV2-44 E DI, II IgG2c 100 none ++
DENV2-46 E DI, II IgG2c 100 none + 2
DENV2-48 E DI, II IgG1 100 none ++
DENV2-50 E DI, II IgG2c 100 none 22
DENV2-53 E DI, II IgG2c 97 DENV1,3 ++
DENV2-58 E DI, II IgG2c 100 none ++
DENV2-60 E ND 0 none ++
DENV2-67 E DIII IgG1 92 none + 2
DENV2-70 E DIII IgG1 100 none ++
DENV2-73 E DIII IgG2c 100 none ++
DENV2-76 E DIII IgG2c 100 DENV1 ++
DENV2-77 E DIII IgG2c 100 DENV1,3,4 ++
DENV2-93 E DIII IgG2c 0 none 22
DENV2-94 E DIII IgG2c 93 DENV1 22
DENV2-96 E DIII IgG2c 100 none ++
DENV2-97 E DIII IgG2c 0 none + 2
DENV2-99 E DIII IgG2c 75 DENV1 + 2
DENV2-104 E DIII IgG2c 100 none ++
DENV2-106 E DIII IgG2c 100 none + 2
a12 mAbs DI/II; 14 mAbs DIII; 1 unknown.
bThe percentage of neutralization was determined by single endpoint plaque reduction neutralization assay on BHK21 cells (adapted from [35]).
cPositivity indicates at least two times background signal.
dn.d. denotes not determined.
doi:10.1371/journal.pone.0029957.t001
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ability of anti-E mAbs to enhance infectivity, we next investigated
to what extent furin activity was required for ADE of st DENV
preparations after opsonization with E antibodies. Initially, the
viral infectivity of st DENV preparations in P388D1 cells was
analyzed in the presence of increasing mAb concentrations. As
expected, all mAbs tested enhanced infectivity of st DENV (Fig.
S1). Enhancement of infection was seen over a broad range of
antibody concentrations: under optimal ADE conditions an
approximately 100-fold increase in virus particle production was
observed. Next, the FI assay was performed at the single mAb
concentration that most efficiently promoted ADE: for the E mAbs
4G2, DV2-48, and DV2-53 a concentration of 400 ng/ml, for
DV2-104 a concentration of 4000 ng/ml, and for DV2-60 and
DV2-96 a 1/10
3 dilution of hybridoma supernatant was used.
Notably, furin activity was necessary for optimal ADE of st DENV
opsonized with anti-E mAbs, as an approximate ,10-fold
reduction in viral infectivity was observed in cells treated with FI
(Fig. 4). Thus, a fraction of the ADE observed with st DENV
preparations is caused by infectivity of fully or partially immature
particles that required furin cleavage.
Immature WNV particles opsonized with anti-E 4G2
induce lethal disease in mice
Because wild type mice do not support DENV replication, and
thus are not a suitable animal model for pathogenesis, we instead
tested the significance of our findings using the well-established
C57BL/6 mouse model of WNV infection [43]. Immature WNV
was produced on LoVo cells, as described before [21,44].
Consistent with our published results, the specific infectivity of
the immature WNV preparation was reduced ,30,000-fold
compared to that of st virus prepared in BHK21 cells. Next, we
evaluated the infectious properties of immature WNV opsonized
with the flavivirus cross-reactive anti-E mAb 4G2 in P388D1 cells
at MOG 10. At 26 hpi, the supernatant was harvested and virus
production was analyzed by plaque assay on BHK21-15 cells. In
agreement with our data obtained for DENV (Fig. 1C), 4G2
promoted viral infectivity of immature WNV (Fig. 5A). Subse-
quently, mice were inoculated by intraperitoneal (IP) injection
with immature WNV particles with and without prior opsoniza-
tion with 4G2. Five mice were used for each experimental
condition, and 3.4610
7 GCPs were inoculated per mouse (based
on 10
4 infectious units for st virus preparations). Mice injected with
immature WNV in the absence of Abs showed no clinical signs of
infection or lethality, confirming that immature WNV by itself is
not infectious (Fig. 5B). In comparison, immature WNV
opsonized with anti-E mAb 4G2 became infectious in mice. At a
mAb concentration of 4 ng/ml 3 out of 5 mice died, at 40 and
400 ng/ml all mice died and at a 4G2 concentration of 4000 ng/
Figure 1. Effect of anti-E mAbs on the infectious properties of fully immature DENV particles. P388D1 cells were infected with immature
(prM-containing) DENV-2 strain 16681 at MOG 1000 in the presence or absence of: (A) anti-prM antibody and st DENV preparation without antibody,
which were used as controls and (B–P) different anti-E mAbs. Prior to infection, immature DENV particles were incubated with varying antibody
concentrations for 1 h at 37uC. At 43 hpi supernatant was harvested and virus production was analyzed by plaque assay on BHK21-15 cells. Data are
expressed as means of at least two independent experiments performed in triplicate. Immature virus in the absence of antibodies was used as a
control in all experiments (n=20), for clarity the average of these results are only plotted in panel 1A. The error bars represent standard deviations
(SD); (n.d.) denotes ‘‘not detectable’’. Student’s t-tests were used to determine significance; *, P,0.01.
doi:10.1371/journal.pone.0029957.g001
Figure 2. Antibodies facilitate binding and internalization of
fully immature DENV particles. Binding of immature and standard
virion preparations to P388D1 cells with and without prior virus
opsonization with antibodies. Virus-cell binding/internalization was
measured after 1 h incubation at 37uC by qPCR analysis. Results are
shown at conditions of efficient ADE for mAbs that promote viral
infectivity. For mAbs that neutralize viral infectivity, a wide antibody
concentration range was tested and the condition at which the highest
number of GCPs bound per cell is observed is depicted. Data are
expressed as means of two independent experiments performed in
triplicate. The error bars represent standard deviations (SD); (n.d.)
denotes ‘‘not detectable’’. Student’s t-tests were used to determine
significance; *, P,0.01.
doi:10.1371/journal.pone.0029957.g002
Figure 3. Antibody dependent enhancement is critically
dependent on furin activity. P388D1 cells were infected with st
DENV or antibody-opsonized immature particles in the presence of
absence of furin inhibitor. Data are expressed as means of three
independent experiments performed in duplicate. The error bars
represent standard deviations (SD); (n.d.) denotes ‘‘not detectable’’.
Student’s t-tests were used to determine significance; *, P,0.01.
doi:10.1371/journal.pone.0029957.g003
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an anti-E mAb directed against DI/II can render immature WNV
infectious in vivo in a dose-dependent manner.
Immune serum induces ADE of immature WNV
The ability of anti-E Abs to render immature particles infectious
could have implications for the development of a safe and
efficacious tetravalent DENV vaccine as all vaccine formulations
in development aim to induce a robust polyclonal response to E.
To test the intrinsic ability of polyclonal anti-E Abs to rescue the
infectivity of immature WNV particles, we analyzed the infectious
properties of immature particles in presence of immune serum
derived from mice vaccinated with E ectodomain. Serum from
mice immunized with the ectodomain of E rendered immature
WNV infectious in P388D1 cells at a broad antibody concentra-
tion range (1/10
2 to 1/10
4 dilution) (Fig. 6A). Furthermore, mice
injected IP with immature WNV (3.4610
7 GCPs/mice) pre-
opsonized with anti-E ectodomain sera succumbed to lethal
infection in a dose-dependent manner (Fig. 6B). At an anti-E
ectodomain serum dilution of 1/10
4 all mice died whereas at a 1/
10
5 serum dilution 2 out of 5 mice succumbed to WNV infection.
Thus, polyclonal antibodies generated in mice upon vaccination
with E ectodomain can render immature virions infectious. These
intriguing results prompted us to evaluate the enhancing
properties of serum derived from mice infected with a sublethal
dose of WNV. First, the serum was subjected to Western blot
analysis to determine the ratio of anti-prM and anti-E antibodies.
Notably and consistent with prior studies [34,45], the vast majority
of anti-virion Abs present in WNV immune serum were directed
against the viral E protein (Fig. 6C). Thereafter, we analyzed the
infectious properties of immature WNV particles opsonized with
increasing concentrations of immune serum (1/10 to 1/10
8
dilution) in P388D1 cells at MOG 10. Enhancement of immature
WNV infectivity was observed at a serum dilution of 1/10
3 to 1/
10
5, with titers 3 to 4 logs higher than those obtained with
immature virus in the absence of antibody (Fig. 6D). Subsequent
in vivo experiments revealed that all mice receiving immune serum
at dilutions of 1/10 to 1/10
4 survived infection, whereas 3 out of 5
animals inoculated with immature WNV opsonized with serum at
a dilution of 1/10
5 succumbed to lethal infection (Fig. 6E).
Discussion
In this study, we demonstrated that, in addition to anti-prM
antibodies [26,28], anti-E antibodies can promote infectivity of
immature DENV by facilitating internalization and maturation of
immature DENV particles in FcyR-expressing cells. Accordingly,
Figure 4. Effect of furin inhibitor on the infectivity of standard
virus preparations. P388D1 cells were infected with antibody-
opsonized st DENV particles in the presence or absence of furin
inhibitor. Standard DENV particles without antibody or opsonized with
anti-prM antibody 70.21 were used as controls. The error bars represent
standard deviations (SD) derived from at least two separate experi-
ments performed in duplicate. Two-tailed Student’s t-tests were used to
determine significance; *, P,0.01.
doi:10.1371/journal.pone.0029957.g004
Figure 5. Effect of anti-E mAb 4G2 on the infectious properties of immature WNV particles in vitro and in vivo. (A) P388D1 cells were
infected with immature WNV opsonized with increasing concentrations of 4G2 at MOG 10. At 26 hpi, the supernatant was harvested and virus
production was analyzed by plaque assay on BHK21-15 cells. Data are expressed as means of at least two independent experiments performed in
duplicate. The error bars represent standard deviations (SD); (n.d.) denotes ‘‘not detectable’’. Student’s t-tests were used to determine significance;
*, P,0.01. (B) Immature WNV was incubated with different concentrations of anti-E 4G2 for 1 hr at 37uC, and injected in mice. A total of 3.4610
7 GCPs
were given per mouse. Five mice were used for each experimental condition.
doi:10.1371/journal.pone.0029957.g005
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we found that enzymatic activity of furin in the target cell was
required for facilitating infectivity of anti-E antibody-opsonized
immature particles. The significance of this finding was confirmed
with WNV, as low concentrations of immune serum promoted
infectivity of immature WNV particles in vitro and in vivo.
Furthermore, detailed investigation of the enhancing properties of
anti-E antibodies in st DENV preparations revealed that enhance-
ment of infection also is promoted by furin activity present within
the target cell. These results demonstrate that anti-E antibodies can
render immature flavivirus particles infectious and that enhance-
ment of infection is modulated by the maturation status of the virus.
The majority of the anti-E mAbs tested in this study bound to
immature DENV particles. While some DI/II- and DIII-specific
anti-E antibodies promoted infection, others did not. In both
situations, the antibodies facilitate binding and uptake of immature
virions into an endocytic or phagocytic pathway of the target cell.
For those mAbs promoting productive infection, we postulate that
the low-pH environment in endosomes induces a structural
transition change in the virion that allows furin to cleave prM to
M allowing membrane fusion and infection. Anti-E mAbs that do
not stimulate viral infectivity may interfere with this conforma-
tional change of the virion prior to furin cleavage, or with the
fusion process itself. Indeed, previous analysis of an anti-E WNV
fusion loop antibody revealed that the fusion loop mAb E53
stabilizes the viral spike complex of immature DENV particles to
such an extent that a lower pH environment is required to trigger
the structural transition change of the virion [30]. In other words,
the fate of the immature DENV-immune complex is determined
in the endocytic/phagocytic pathway of the cell.
A distinct enhancement pattern was observed for ADE of
immature virus opsonized with anti-E mAbs compared to that of
anti-prM mAbs. ADE of anti-E opsonized immature particles only
was observed at high antibody concentration, whereas for anti-
Figure 6. Effect of immune sera on the infectious properties of immature WNV particles. Infectivity and mice experiments were
performed as described in the legend to Fig. 5. (A, B) immune sera from mice prior vaccinated with E ectodomain. (D, E) Immune serum derived from
mice prior infected with a sublethal dose of st WNV. (A, D) Values depicted on the x axis represent dilution factors. The error bars represent standard
deviations (SD); (n.d.) denotes ‘‘not detectable’’, (PMS) denotes polyclonal mouse serum. Student’s t-tests were used to determine significance;
*, P,0.01. (C) Western blot analysis of immune serum from mice prior infected with a sublethal dose of WNV. On the SDS-PAGE gel, purified
immature WNV was loaded.
doi:10.1371/journal.pone.0029957.g006
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concentrations. One possible explanation for this is that fully
immature particles have relatively few accessible epitopes available
for engagement by our panel of anti-E mAbs. A smaller number of
available epitopes might require a higher fractional occupancy and
thus higher concentrations, to reach a stoichiometry sufficient for
enhancement. Indeed, structural data confirm that in immature
flaviviruses, the E protein is largely covered by the prM protein,
which could limit epitope exposure of some E protein epitopes
[12,20,46,47]. Consistent with this hypothesis, several of our mAbs
(DV2-29, DV2-44, DV2-48, DV2-58, DV2-70, DV2-73, DV2-76,
DV2-77, DV2-77, DV2-96 and DV2-104) were strongly neutral-
izing against st DENV preparations [35] but showed little
inhibitory activity of opsonized immature particles even at
concentrations that were 10–100-fold above their EC50. While
engagement of a relatively small number of accessible E protein
epitopes was sufficient for enhancement of st WNV preparations
on CD32-expressing K562 cells [42] the precise stoichiometry of
enhancement for immature virions or other cell types that express
distinct sets of FccR remains to be determined.
Coupled with prior studies, our observation that both anti-prM
and anti-E antibodies can promote infectivity of immature DENV
particles supports the hypothesis that immature DENV particles
are important in disease pathogenesis [26,28]. Whereas most prM
antibodies are poorly neutralizing and thus, efficiently enhance
infection of partially mature and immature particles, anti-E
antibodies, depending on the concentration and epitope accessi-
bility can neutralize or enhance infection of immature particles.
During homologous re-infection with the same serotype, the anti-E
antibodies may more readily neutralize infection whereas during
heterologous re-infection with a different serotype cross-reactive
anti-prM and anti-E antibodies may bind yet not neutralize,
setting the stage for ADE. The importance of virion maturation in
controlling viral infectivity during natural infection remains
unclear. While it is unknown what state of maturation DENV
particles exists in vivo, prM antibodies appear frequently in the
context of the human humoral response [28]. Our in vivo data
with WNV, suggests that immature virions opsonized with serum
Abs can promote enhanced infection and disease. As such,
evaluation of the enhancing and neutralizing properties of anti-
DENV serum with virions with distinct maturation states may help
to define better correlates of protection or pathogenesis during
secondary heterosubtypic infection.
The observation that the maturation state of a virus preparation
influences the neutralizing or enhancing potential of an antibody
has implications for DENV vaccine development. This report
clearly shows that antibodies generated upon vaccination with E
ectodomain can facilitate infectivity of immature WNV particles.
Also, low concentrations of immune serum from mice prior infected
with a sublethal dose of WNV stimulated viral infectivity of
immature virions. However, our analysis also shows that a number
of antibodies recognizing E DI/II and DIII epitopes exist that do
not promote the infectivity of immature particles. Future detailed
examination of these antibodies maydefinenovel targets forvaccine
refinement. In general, immunization or boosting strategies that
minimize induction of anti-prM or cross-reactive anti-E antibodies
may limit enhancement of infection of partially mature and
immature particles during subsequent natural challenge.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All animal
experimental protocols were approved by the Institutional Animal
Care and Use Committee of Yale University (Protocol Permit
Number: 2008-07941) and experiments were done in a Biosafety
Level 3 animal facility according to the regulations of Yale
University. All efforts were made to minimize suffering.
Cells
Aedes albopictus C6/36 cells were maintained in minimal essential
medium (Life Technologies) supplemented with 10% fetal bovine
serum (FBS), 25 mM HEPES, 7.5% sodium bicarbonate,
penicillin (100 U/ml), streptomycin (100 mg/ml), 200 mM gluta-
mine and 100 mM nonessential amino acids at 30uC, 5% CO2.
Baby hamster Kidney (BHK21) and BHK21 clone 15 cells
(BHK21-15) cells were cultured in DMEM (Life Technologies)
containing 10% FBS, penicillin (100 U/ml), streptomycin
(100 mg/ml), 10 mM HEPES, and 200 mM glutamine. Human
adenocarcinoma LoVo cells were cultured in Ham’s medium
(Invitrogen) supplemented with 20% FBS at 37uC, 5% CO2.
Mouse macrophage P388D1 cells were maintained in DMEM
supplemented with 10% FBS, penicillin (100 U/ml), and strepto-
mycin (100 mg/ml), sodium bicarbonate (Invitrogen, 7,5% solu-
tion) and 1.0 mM sodium pyruvate (GIBCO) at 37uC, 5% CO2.
Virus growth
DENV-2 strain 16681 and WNV strain NY385-99 were
propagated on C6/36 cells and BHK21 cells respectively, as
described before [21,38]. Immature DENV and WNV particles
were produced on LoVo cells as described previously [21]. Briefly,
LoVo cells were infected at MOI 5 for DENV and MOI 4 for
WNV. Virus inoculum was removed after 1.5 hr and fresh
medium was added after washing the cells three times with PBS.
At 72 hpi, the medium containing the virus particles was
harvested, cleared from cellular debris by low-speed centrifuga-
tion, aliquoted, and stored at 280uC. The specific infectivity of the
DENV and WNV preparations was determined by measuring the
number of infectious units by plaque assay on BHK21-15 cells and
the number of GCPs by quantitative PCR (qPCR) analysis, as
described previously [21,38].
qPCR
To determine the number of GCP, we extracted viral RNA by
use of a QIAamp viral RNA mini kit (QIAGEN, Venlo, The
Netherlands). cDNA was synthesized from viral RNA by RT-
PCR. For DENV we used a published protocol [38]. For WNV,
the forward primer 59-GTT GGC GGC TGT TTT CTT TC-39,
and the reverse primer 59-GGG ATC TCC CAG AGC AGA
ATT-39 and a TaqMan probe 59-FAM-AAT GGC TTA TCA
CGA TGC CCG CC-TAMRA-39 (Eurogentec, Seraing, Belgium)
was used. DNA was amplified for 40 cycles (15 s at 95uC and 60 s
at 60uC) on a StepOne Real-Time PCR instrument (Applied
Biosystems, Carlsbad, CA) and the concentration GCPs was
determined using a standard curve based on a cDNA plasmid
encoding the nonstructural genes of WNV NY99 (kind gift from
Dr. G.P. Pijlman, Wageningen University, The Netherlands).
ELISA
The binding properties of anti-E antibodies to immature virus
particles were assessed with a three-layer ELISA. Briefly,
microtiter ELISA plates (Greiner bio-one) were coated with
5610
8 GCP of purified virus preparations per well in 100 ml
coating buffer, overnight. After blocking with 2% milk in coating
buffer for 120 min, 100 ml of two-fold serial dilutions of anti-E
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in triplicate. Subsequently, 100 ml of horseradish peroxidase-
conjugated goat anti-mouse IgG isotype antibody (Southern
Biotech) was applied for 1 hr. All incubations were performed at
37uC. Staining was performed using o-phenylene-diamine (OPD)
(Eastman Kodak Company) and absorbance was read at 492 nm
(A492) with an ELISA reader (Bio-tek Instruments, Inc.). Samples
were considered positive when the absorbance was two times
higher than the background signal.
Infectivity assays
Virus or virus-antibody complexes were added to a monolayer
(2610
5) of P388D1 cells in 24 wells plates (Costar), at a multiplicity
of genome-containing particles (MOG) per cell of 1000 for DENV
and 10 for WNV. After 1.5 h incubation at 37uC, fresh medium
was added to the cells. At 26 hpi for WNV and 43 hpi for DENV,
the medium was harvested and virus production was analyzed by
plaque assay on BHK21-15 cells, as described previously [48]. The
limit of detection in the plaque assay is 20 PFU/ml. In furin
inhibitor experiments, cells were treated with 25 mM of furin-
specific inhibitor, decanoyl-L-arginyl-L-valyl-L-lysyl-L-arginyl-
chloromethylketone (decRRVKR-CMK) (Calbiochem) prior to
and during virus infection [26].
Binding assays
To determine the number of bound and/or internalized
genome-containing particles per cell, virus or virus-antibody
complexes were incubated with 2610
5 P388D1 cells at MOG
1000 for 1 h at 37uC. Subsequently, cells were washed three times
with ice-cold PBS containing MgCl2 and CaCl2 (Life Technolo-
gies) to remove unbound virus-antibody complexes. Viral RNA
was extracted subsequently from the cells using the QIAamp Viral
RNA mini Kit (QIAGEN). Thereafter, cDNA was synthesized
from the viral RNA with reverse transcription-PCR (RT-PCR),
and the copy number was quantified using qPCR [38]. The limit
of detection is 1.6 GCPs bound per cell.
Immune sera and Western Blot analysis
Immune WNV serum was produced by injecting mice IP with a
sublethal dose of a st WNV preparation. At day 28, blood was
collected by orbital puncture. Plasma was obtained, aliquoted, and
stored at 4uC. Anti-E immune sera was obtained in the same
manner from mice injected IP with the E ectodomain. Both sera
were tested via Western blot analysis for reactivity to E protein as
well as for ability to neutralize wt WNV in vitro. For Western blot
analysis, 3.0610
9 GCP of purified immature WNV was loaded on
12.5% SDS polyacryramide gels under non-reducing conditions
and electroblotted in the presence of two concentrations of
immune serum, 1:1000 and 1:100.
Mouse experiments
All animal experimental protocols were approved by the
Institutional Animal Care and Use Committee of Yale University
and experiments were done in a Biosafety Level 3 animal facility
according to the regulations of Yale University. Female C57BL/6
mice (6 weeks old) were infected by IP injection with immature
WNV prior opsonized with increasing concentrations anti-E mAb
4G2 or immune serum. Five mice were used for each experimental
condition, and 3.4610
7 GCPs were inoculated per mouse and
mice were followed for 15 days.
Supporting Information
Figure S1 Effect of mAbs on the infectious properties of
standard DENV preparations. (A–G) P388D1 cells were
infected with DENV-2 strain 16681 at MOG 1000 in the presence
or absence of different anti-E mAbs. At 43 hpi supernatant was
harvested and virus production was analyzed by plaque assay on
BHK21-15 cells. Data are expressed as means of at least two
independent experiments. St virus in the absence of antibodies was
used as a control in all experiments (n=6), for clarity the average
of these results are only plotted in panel A. The error bars
represent standard deviations (SD). Two-tailed Student’s t-tests
were used to determine significance; *, P,0.01.
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